Juwon Park to Antineoplastic Agents
This is a "connection" page, showing publications Juwon Park has written about Antineoplastic Agents.
Connection Strength
0.789
-
Park J, Bae EK, Lee C, Choi JH, Jung WJ, Ahn KS, Yoon SS. Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-?B-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. BMB Rep. 2014 May; 47(5):274-9.
Score: 0.293
-
Park J, Kim KI, Koh Y, Won NH, Oh JM, Lee DS, Kim BK, Ahn KS, Yoon SS. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model. Exp Hematol. 2010 Sep; 38(9):773-81.
Score: 0.223
-
Park J, Ahn KS, Bae EK, Kim BS, Kim BK, Lee YY, Yoon SS. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells. Anticancer Drugs. 2008 Sep; 19(8):777-82.
Score: 0.198
-
Kim BS, Bae E, Kim YJ, Ahn KS, Park J, Rhee JY, Lee YY, Kim Y, Lee D, Kim BK, Yoon SS. Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia. Anticancer Drugs. 2007 Jul; 18(6):641-7.
Score: 0.046
-
Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, Fein M, Rasch MG, Tan YX, Qiu J, Park J, Sinha P, Bissell MJ, Frengen E, Werb Z, Egeblad M. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012 Apr 17; 21(4):488-503.
Score: 0.016
-
Kim KI, Park J, Ahn KS, Won NH, Kim BK, Shin WG, Yoon SS, Oh JM. Molecular characterization and prognostic significance of FLT3 in CML progression. Leuk Res. 2010 Aug; 34(8):995-1001.
Score: 0.014